We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Polyclonal Breast Cancer Metastases Are Generated by Clusters of Migrating Cells

By LabMedica International staff writers
Posted on 14 Feb 2016
A recent study confirmed that, contrary to conventional wisdom, cancer metastasis usually depends on the release of clusters of cells rather than single cells from the primary tumor.

Conventional models of cancer progression propose that single cells leave the primary tumor, enter the circulation, and seed metastases based on the clonal type of that cell. More...
However, metastases can contain multiple clones, raising the question of how polyclonal metastases are formed.

To answer this question investigators at Johns Hopkins University (Baltimore, MD, USA) used multicolor lineage tracing to follow red or green tagged cells as they escaped from a primary tumor (in culture or in a mouse model) to form daughter tumors.

They reported in the February 1, 2016, online edition of the journal Proceedings of the National Academy of Sciences of the United States of America (PNAS) that polyclonal seeding by cell clusters was the most frequent mechanism in a common mouse model of breast cancer, accounting for more than 90% of metastases. They directly observed multicolored tumor cell clusters across major stages of metastasis, including collective invasion, local dissemination, intravascular emboli, circulating tumor cell clusters, and micrometastases.

Experimentally aggregating tumor cells into clusters induced a greater than 15-fold increase in colony formation in three-dimensional in vitro gel culture and a greater than 100-fold increase in metastasis formation in a mouse model.

The investigators found that the most invasive clones frequently expressed the epithelial cytoskeletal protein, keratin 14 (K14), which regulated cell-cell adhesion, cell-matrix adhesion, and immune evasion. When K14 expression was blocked, there was a dramatic reduction in formation of distant metastases combined with disrupted expression of multiple metastasis effectors.

“We found that cancer cells do two things to increase their chances of forming a new metastasis,” said senior author Dr. Andrew Ewald, associate professor of cell biology at Johns Hopkins University. “They turn on a molecular program that helps them travel through a diverse set of environments within the body, and they travel in groups.”

“Because most chemotherapeutic drugs target proliferating cells, metastasizing cells would not be killed by them, leaving patients vulnerable to new tumors,” said Dr. Ewald. “Our discoveries add to knowledge that could help overcome that vulnerability. We found that the activity of dozens of genes differs between proliferating and metastasizing cells. Since many of those genes encode cell surface proteins, we hope these findings might eventually be used to develop new drugs that target metastasizing cells.”

Related Links:
Johns Hopkins University



New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Thyroid Test
Anti-Thyroid EIA Test
New
Benchtop Thermomixer
Biometra TS1 ThermoShaker
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.